News und Analysen
Canopy Growth: Wie gewonnen, so zerronnen?
Zeitgleich mit Wechsel des Finanzchefs vom "Corona"-Brauer Constellation Brands an die Spitze von Canopy Growth (WKN: A140QA) scheint das Vertrauen in die grüne Wachstumsbranche zurückgekehrt (wir b
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the
Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment
plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that its collaborators at The Institute of Cancer Research, London, presented results from the cohort of patients in
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that the primary endpoint
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's drug neratinib are being presented at the 2019 San
Humana Announces New Care Coordination Services for Members With Kidney Disease
Leading health and well-being company Humana Inc. (NYSE: HUM) is expanding its care management portfolio by teaming up with two specialized care management companies to offer personalized
NanoString Announces the Creation of the GeoMx Breast Cancer Consortium
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced the formation of the GeoMx™ Breast Cancer Consortium (GBCC).
The
GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210006078/en/
Figure 1. LHON Natural History from Interim Analysis
Evotec: "Seuchenjahr" 2019 – wird 2020 besser?
Evotec-Aktien (WKN: 566480) gehörten in 2019 nicht zu den absoluten Überfliegern der deutschen Aktienindizes. Seit Jahresstart steht eine Performance von „mickrigen“ +19,78% auf der Kurstafel
Premier Inc. Exceeds Other Enterprise Resource Planning Software Vendors in Services Satisfaction
Premier Inc.’s (NASDAQ: PINC) leading enterprise resource planning (ERP) solution has again been named a top performer by KLAS Research, a healthcare IT data and insights company.
The recognition
Waters Corporation Announces 2025 Sustainability Goals
Waters Corporation (NYSE:WAT) today announced its 2025 sustainability goals and simultaneously announced a commitment to report its sustainability progress annually. These goals were developed
Aurinia Prices US$166.7 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
Transgene Announces Investor Meetings for January 2020
Regulatory News:
Transgene (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional investors at the LifeSci
ArQule: +100% nach Milliarden-Übernahme
Das amerikanische Pharmakonglomerat Merck & Co. (WKN: A0YD8Q) akquiriert den Biotechforscher ArQule (WKN: 903396) für 20 US-Dollar je Aktie. Merck legt für die Übernahme 2,7 Milliarden US-Dollar in
ArQule: +100% nach Milliarden-Übernahme
Das amerikanische Pharmakonglomerat Merck & Co. (WKN: A0YD8Q) akquiriert den Biotechforscher ArQule (WKN: 903396) für 20 US-Dollar je Aktie. Merck legt für die Übernahme 2,7 Milliarden US-Dollar in
Xencor Presents Initial Data from Phase 1 Study of XmAb®13676 in B-cell Malignancies at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today
Lantheus Enters into Strategic Collaboration with CarThera for Use of Microbubbles in Combination with SonoCloud® System for Treatment of Glioblastoma
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative
ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting
ArQule, Inc. (Nasdaq: ARQL) today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant
Sangamo Announces Preliminary Results From the First Three Patients in a Phase 1/2 Study Evaluating ST-400 Ex Vivo Gene-edited Cell Therapy in Beta Thalassemia
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preliminary results from the first three patients treated in the Phase 1/2 THALES study evaluating
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191208005050/en/
The National Eye Hospital (CHNO) of the Quinze-Vingt